The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer

M Boussageon, A Swalduz, M Pérol - Expert Review of Anticancer …, 2021 - Taylor & Francis
Introduction EGFR-tyrosine kinase inhibitors (TKIs) changed the natural history of EGFR-
mutant advanced NSCLC patients, but acquired resistance is inevitable. New strategies are …
被引用次数：6 相关文章

The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer.

M Boussageon, A Swalduz, M Pérol - Expert Review of Anticancer …, 2021 - europepmc.org
EGFR-tyrosine kinase inhibitors (TKIs) changed the natural history of EGFR-mutant
advanced NSCLC patients, but acquired resistance is inevitable. New strategies are being …

The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer

M Boussageon, A Swalduz… - Expert review of …, 2021 - pubmed.ncbi.nlm.nih.gov
Introduction EGFR-tyrosine kinase inhibitors (TKIs) changed the natural history of EGFR-
mutant advanced NSCLC patients, but acquired resistance is inevitable. New strategies are …